The effect of Fuzheng Huayu tablet post Kasai surgery in Biliary atrsia: a multicenter randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037187

Enrollment

Unknown

Registered

2020-08-27

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biliary atresia

Interventions

experimental group:Fuzheng Huayu,0.5tablet po tid

control :no intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.biliary atresia diagnosed by liver biopsy or cholangiography,and Kasai surgery; 2.Informed Consent Form signned by statutory guardian.

Exclusion criteria

Exclusion criteria: 1.with no Standard medication depengding on Guidelines for diagnosing&treating bilim'y atresia(2018 Edition); 2.with known immune deficiency; 3.with hepatitis(hepatitis B/C virus)and HIV; 4.with severe surgical complication(massive bleeding,obstruction) within 72 hours after surgery; 5.with no Informed Consent Form; 6.with other serious systemic diseases.

Design outcomes

Primary

Measure	Time frame
jaundice clearance rate;	—

Secondary

Measure	Time frame
native liver survival rate;AST;ALT;height;weight;ligandin;liver stiffness;Portal vein diameter;Portal velocity;	—

Countries

China

Contacts

Public ContactLv Zhibao

Shanghai Children's Hospital

lvzhibao@sohu.com+86 18930658851

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026